BASEL, Switzerland
,
April 1, 2022
(press release)
–
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies. Membership will allow Lonza to engage in and contribute to discussions on current regulations and standards with regulatory bodies and support the shaping of national and international trends and requirements. Inhaled drug products for nasal or pulmonary delivery are increasing in popularity due to the global prevalence of respiratory diseases. The lung’s absorptive capacity also continues to be explored as a delivery point for both local and systemic applications, thereby decreasing adverse medical events by sparing healthy tissues and improving patient convenience and compliance. Matthew Ferguson, Technology Head, Respiratory Delivery, Lonza, commented: “Locally administered drug products represent an attractive means of delivery for lung indications thanks to their decreased off-target activity. However, the development of stable dry powder formulations remains a challenge. Lonza’s participation in the IPAC-RS consortium will enable us to contribute to discussions on regulatory guidance that will improve the manufacturing process of these innovative products globally.” IPAC-RS is an international association aimed at the advancement of orally inhaled and nasal drug products. IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals and discussions with regulatory bodies. Membership in IPAC-RS will enable an appropriate exchange of information and experience in the areas of particle engineering, inhalation testing, complex and combination products, devices, and packaging. Lonza Inhalation Formulation Development Services will be able to participate in joint industry discussions focused on emerging international regulatory and scientific challenges facing the orally inhaled and nasal drug products (OINDP). Jason Bertola, Executive Director, Commercial Development, Small Molecules, Lonza, added: “Drug delivery via the lung is complex but gaining importance in the market with significant opportunities in unmet clinical needs. This results in increasing demand for formulation development, particle engineering and manufacturing of inhalation products, with an emphasis on speed. At Lonza, we understand this challenge and plan to contribute and further our expertise in this area to better serve our customers.” To learn more about Lonza’s inhalation formulation development services, visit https://pharma.lonza.com/technologies-products/particle-engineering-inhalation-applications
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
